论文部分内容阅读
目的分析乳腺癌患者血清与血浆中可溶性L1细胞黏附分子(s L1)含量的差异,探讨s L1含量检测的血标本的选择。方法采用数字随机法收集10例乳腺癌患者和8例健康对照者的血清和血浆标本,采用酶联免疫吸附试验检测s L1含量,通过秩和检验和相关分析,比较血清和血浆、患者和对照组s L1含量的差异和相关性。结果健康对照者血浆和血清均难以检测到s L1。乳腺癌患者血浆s L1含量(480.92±55.92)pg显著高于血清s L1含量(310.46±104.23)pg,两者比较差异有统计学意义(P<0.01);患者血浆s L1含量范围349.21~544.03 pg,中位数495.85 pg,血清s L1含量范围为165.48~503.21 pg,中位数318.18 pg,故血浆含量检测更稳定。乳腺癌患者血浆与血清s L1含量无相关性(γs=0.236,P=0.511)。结论乳腺癌患者血清和血浆s L1含量存在明显差异,选择血浆作为临床检验标本更能真实反映血液中s L1含量,且数值更稳定。
Objective To analyze the difference of soluble L1 cell adhesion molecule (s L1) in serum and plasma of patients with breast cancer, and to explore the choice of serum samples for detection of s L1. Methods Serum and plasma samples from 10 breast cancer patients and 8 healthy controls were collected by digital randomization method. The levels of s L1 were detected by enzyme-linked immunosorbent assay (ELISA), rank sum test and correlation analysis were used to compare serum and plasma, patients and controls Differences and correlations of group s L1 content. Results It was difficult to detect s L1 in plasma and serum of healthy controls. The serum s L1 level in patients with breast cancer (480.92 ± 55.92) pg was significantly higher than that of serum s L1 (310.46 ± 104.23) pg, with significant difference between the two groups (P <0.01). The s L1 level in plasma was 349.21 ~ 544.03 pg, the median 495.85 pg, serum s L1 content range of 165.48 ~ 503.21 pg, the median 318.18 pg, so the detection of plasma levels more stable. There was no correlation between the level of serum sLl in plasma of patients with breast cancer (γs = 0.236, P = 0.511). Conclusion The serum and plasma s L1 levels in patients with breast cancer are significantly different. The selection of plasma as a clinical laboratory specimen can more accurately reflect the content of s L1 in the blood and the value is more stable.